- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hormone receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 910KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 503KB)
Sacituzumab govitecan – July 2023
Sacituzumab govitecan: Powder for injection 180 mg; Trodelvy® - July 2023
Last updated
10 November 2023